Augusto Miravalle
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Augusto Miravalle has a total of 44 co-authors. Here are the top co-authors by number of shared publications:
- Jonathan D. Campbell
National Pharmaceutical Council , Washington, DC 20006
2 shared publications - Robert Brett McQueen
Department of Clinical Pharmacy, University of Colorado Anschutz Medical Campus, Aurora, USA
2 shared publications - Timothy Vollmer
Department of Neurology, Rocky Mountain Multiple Sclerosis Center at Anschutz Medical Campus, University of Colorado Denver
2 shared publications - Aaron M. Carlson
Department of Neurology, University of Colorado School of Medicine, Aurora
1 shared publication - Aleksandar C. Blubaum
Department of Urology, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, Oklahoma City, Oklahoma
1 shared publication Alina Rich
University of Colorado School of Medicine Aurora CO United States
1 shared publication
Latest Publications
- Open Access
- 1 September 2024
- Published by Wolters Kluwer Health in JU Open Plus
- Vol. 2 (9)
Severity of Lower Urinary Tract Symptoms Predicts Neurologic Quality of Life in Patients With Multiple Sclerosis
Introduction: Lower urinary tract symptoms (LUTSs) are underreported in patients with multiple sclerosis (MS). We aim to define the incidence of LUTSs in patients with MS and their effect on neurologic quality of life. Materials and Methods: We identified patients presenting to the neurology clinic for routine follow-up for multiple sclerosis. Each patient responded to validated questionnaires regarding urinary quality of life using the Bladder Control Scale (BLCS) from the Multiple Sclerosis Quality-of-Life Inventory (MSQLI) and overall Quality of Life in Neurological Disorders (NeuroQOL). A retrospective chart review was performed to assess for the presence of lower urinary tract symptoms. Overall neurologic quality of life was measured in the presence and absence of LUTS, and P-values were calculated using the Student t test. A urinary quality-of-life score was correlated with an overall neurologic quality-of-life score using the Spearman rank correlation coefficient. Results: The study included 91 patients who completed the validated questionnaires. Of the 91 patients, 85 (93%) described the presence of at least 1 lower urinary tract symptom. The most common symptoms were urgency (84%), frequency (69%), incontinence (54%), and retention (38%). Seventy-two (79%) patients reported that LUTS negatively affected urinary quality of life. The presence of LUTS negatively affected the overall neurologic quality of life. Urinary quality of life was predictive of the overall neurologic quality of life (−0.22, P = .04). Conclusions: LUTSs are very common in patients with MS, and they not only significantly affect but also predict the overall neurologic quality of life.
- 1 September 2024
- Published by Wolters Kluwer Health in JU Open Plus
- Vol. 2 (9)
Open AccessSeverity of Lower Urinary Tract Symptoms Predicts Neurologic Quality of Life in Patients With Multiple Sclerosis
Introduction: Lower urinary tract symptoms (LUTSs) are underreported in patients with multiple sclerosis (MS). We aim to define the incidence of LUTSs in patients with MS and their effect on neurologic quality of life. Materials and Methods: We identified patients presenting to the neurology clinic for routine follow-up for multiple sclerosis. Each patient responded to validated questionnaires regarding urinary quality of life using the Bladder Control Scale (BLCS) from the Multiple Sclerosis Quality-of-Life Inventory (MSQLI) and overall Quality of Life in Neurological Disorders (NeuroQOL). A retrospective chart review was performed to assess for the presence of lower urinary tract symptoms. Overall neurologic quality of life was measured in the presence and absence of LUTS, and P-values were calculated using the Student t test. A urinary quality-of-life score was correlated with an overall neurologic quality-of-life score using the Spearman rank correlation coefficient. Results: The study included 91 patients who completed the validated questionnaires. Of the 91 patients, 85 (93%) described the presence of at least 1 lower urinary tract symptom. The most common symptoms were urgency (84%), frequency (69%), incontinence (54%), and retention (38%). Seventy-two (79%) patients reported that LUTS negatively affected urinary quality of life. The presence of LUTS negatively affected the overall neurologic quality of life. Urinary quality of life was predictive of the overall neurologic quality of life (−0.22, P = .04). Conclusions: LUTSs are very common in patients with MS, and they not only significantly affect but also predict the overall neurologic quality of life.
- Open Access
- 1 February 2021
- Published by Taylor & Francis in Neurodegenerative Disease Management
- Vol. 11 (2) , 99-111
CLICK-MS and MASTER-2 Phase IV Trial Design: Cladribine Tablets in Suboptimally Controlled Relapsing Multiple Sclerosis
Cladribine tablets 10 mg (3.5 mg/kg cumulative dose over 2 years) are approved for the treatment of relapsing forms of multiple sclerosis (MS), including relapsing-remitting MS and active secondary...
- 1 February 2021
- Published by Taylor & Francis in Neurodegenerative Disease Management
- Vol. 11 (2) , 99-111
Open AccessCLICK-MS and MASTER-2 Phase IV Trial Design: Cladribine Tablets in Suboptimally Controlled Relapsing Multiple Sclerosis
Cladribine tablets 10 mg (3.5 mg/kg cumulative dose over 2 years) are approved for the treatment of relapsing forms of multiple sclerosis (MS), including relapsing-remitting MS and active secondary...
- Open Access
- 1 July 2020
- Published by SAGE Publications in Multiple Sclerosis Journal – Experimental, Translational and Clinical
- Vol. 6 (3)
Anti-JCV antibody index does not change during ocrelizumab-treatment
Objective: To prospectively assess anti-JCV antibody index (AI) and its relationship to immunoglobulin levels in ocrelizumab-treated MS patients. Methods: Monocentric prospective observational study over 24 months assessing anti-JCV AI and immunoglobulin levels in MS patients before and after initiation of ocrelizumab. Results: No significant change in anti-JCV AI titers was observed 458 ± 300 days after initiation of ocrelizumab (n = 45, 0.7 ± 2.21 vs. 0.6 ± 2.06, p = 0.8). Seroconversion occurred in 1/20 initially anti-JCV seronegative patients. There was no correlation between changes in anti-JCV AI and immunoglobulins. Conclusion: Treatment with ocrelizumab is not associated with an increase in anti-JCV AI titers.
- 1 July 2020
- Published by SAGE Publications in Multiple Sclerosis Journal – Experimental, Translational and Clinical
- Vol. 6 (3)
Open AccessAnti-JCV antibody index does not change during ocrelizumab-treatment
Objective: To prospectively assess anti-JCV antibody index (AI) and its relationship to immunoglobulin levels in ocrelizumab-treated MS patients. Methods: Monocentric prospective observational study over 24 months assessing anti-JCV AI and immunoglobulin levels in MS patients before and after initiation of ocrelizumab. Results: No significant change in anti-JCV AI titers was observed 458 ± 300 days after initiation of ocrelizumab (n = 45, 0.7 ± 2.21 vs. 0.6 ± 2.06, p = 0.8). Seroconversion occurred in 1/20 initially anti-JCV seronegative patients. There was no correlation between changes in anti-JCV AI and immunoglobulins. Conclusion: Treatment with ocrelizumab is not associated with an increase in anti-JCV AI titers.
- 5 April 2016
- Published by Wolters Kluwer Health in Neurology
- Vol. 86 (16_supplem)
Turning Neurophobia into Neurophoria: A Needs Assessment of Medical Student Education (P2.370)
- 5 April 2016
- Published by Wolters Kluwer Health in Neurology
- Vol. 86 (16_supplem)
Turning Neurophobia into Neurophoria: A Needs Assessment of Medical Student Education (P2.370)
- 5 April 2016
- Published by Wolters Kluwer Health in Neurology
- Vol. 86 (16_supplem)
Increasing Faculty Involvement in Educational Activities (P2.366)
- 5 April 2016
- Published by Wolters Kluwer Health in Neurology
- Vol. 86 (16_supplem)
Increasing Faculty Involvement in Educational Activities (P2.366)
- 5 April 2016
- Published by Wolters Kluwer Health in Neurology
- Vol. 86 (16_supplem)
Characteristics of a Hispanic Multiple Sclerosis Population Cohort at a Large Academic Center (P1.388)
- 5 April 2016
- Published by Wolters Kluwer Health in Neurology
- Vol. 86 (16_supplem)
Characteristics of a Hispanic Multiple Sclerosis Population Cohort at a Large Academic Center (P1.388)
- 23 July 2015
- Published by Springer Nature in Current Neurology and Neuroscience Reports
- Vol. 15 (9) , 1-7
Immune-Mediated Neurological Disorders
Autoimmune disorders are increasingly recognized causes of several neurological disorders leading to significant clinical disability. This article reviews recent developments in our understanding on the pathophysiology, clinical presentations, and diagnoses of selected immune-mediated neurological disorders. It also provides a brief summary of current theories on autoimmunity and the role that certain environmental factors play in the development of immune-mediated neurological disorders. Recently recognized biomarkers might play a pathogenetic role or simply serve as a diagnostic tool.
- 23 July 2015
- Published by Springer Nature in Current Neurology and Neuroscience Reports
- Vol. 15 (9) , 1-7
Immune-Mediated Neurological Disorders
Autoimmune disorders are increasingly recognized causes of several neurological disorders leading to significant clinical disability. This article reviews recent developments in our understanding on the pathophysiology, clinical presentations, and diagnoses of selected immune-mediated neurological disorders. It also provides a brief summary of current theories on autoimmunity and the role that certain environmental factors play in the development of immune-mediated neurological disorders. Recently recognized biomarkers might play a pathogenetic role or simply serve as a diagnostic tool.
- 1 March 2014
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 3 (2) , 227-236
Burden of multiple sclerosis on direct, indirect costs and quality of life: National US estimates
- 1 March 2014
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 3 (2) , 227-236
Burden of multiple sclerosis on direct, indirect costs and quality of life: National US estimates
- 12 February 2013
- Published by Wolters Kluwer Health in Neurology
- Vol. 80 (7_suppleme)
Direct Costs, Indirect Costs, and Quality of Life Burden of Multiple Sclerosis: National US Estimates (P03.201)
- 12 February 2013
- Published by Wolters Kluwer Health in Neurology
- Vol. 80 (7_suppleme)
Direct Costs, Indirect Costs, and Quality of Life Burden of Multiple Sclerosis: National US Estimates (P03.201)
- 6 December 2011
- Published by Taylor & Francis
- p. 6-25
Current guidelines and standard treatments of RR-MS
- 6 December 2011
- Published by Taylor & Francis
- p. 6-25
Current guidelines and standard treatments of RR-MS